Zum Hauptinhalt springen
xMedica

NCT07321899ClinicalTrials.gov

Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation

Transcatheter Tricuspid Valve Replacement Using the Medtronic Intrepid™ TTVR System in Patients With Severe Symptomatic Tricuspid Regurgitation - PATHFINDER

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation.

Interventionell1.186 Teilnehmende gesucht20 Studienzentren1 Land

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-01-07; recorded start 2026-09-11
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 19 other studies in this databaseCounted from the lead sponsor named in the record (Medtronic Cardiovascular)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding7/20

    Single-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 4 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,186 participants (target), run at 20 sites.

How this score is built
  • Enrolment31/40

    1,186 participants (target)

  • Site count7/25

    4 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 179 months

  • Sponsor scale4/10

    Medtronic Cardiovascular has led 19 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation.

Prospective, global, pre-market, interventional, multi-center, randomized controlled pivotal trial to evaluate the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System compared to Edwards EVOQUE TTVR System in symptomatic patients with severe or greater tricuspid regurgitation.

Erkrankungen

  • Severe Tricuspid Regurgitation

Eignung

Eignung
GeschlechtAlle
Alter18 Years – Kein Höchstalter
Gesunde FreiwilligeNein

Eignung im Wortlaut des Registers

Inclusion Criteria: * Age ≥18 years at the time of consent. * Severe symptomatic tricuspid regurgitation (TR) despite optimal medical therapy (OMT). * Local site multidisciplinary heart team experienced in tricuspid valve therapies agrees that the subject is appropriate for TTVR. Exclusion Criteria: * Any tricuspid device currently in place. * Anatomic contraindications. * Need for emergent or urgent surgery. * Left ventricular ejection fraction \<25%.

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypInterventionell
PhaseNicht zutreffend
ZuteilungRandomisiert
InterventionsmodellPARALLEL
Primäres ZielTREATMENT
VerblindungSINGLE (1)
Teilnahme1.186 Teilnehmende gesucht

Sponsor und Mitwirkende

  • Medtronic Cardiovascular Sponsor

Studienarme und Interventionen

  • Medtronic Intrepid™ TTVREXPERIMENTAL

    Transcatheter tricuspid valve replacement with Medtronic Intrepid™ TTVR System in patients with severe or greater tricuspid regurgitation.

  • Edwards EVOQUE TTVRACTIVE_COMPARATOR

    Transcatheter tricuspid valve replacement with Edwards EVOQUE TTVR in patients with severe or greater tricuspid regurgitation.

  • Single Arm RegistryEXPERIMENTAL

    Transcatheter tricuspid valve replacement with Medtronic Intrepid™ TTVR System in patients with severe or greater tricuspid regurgitation who are not eligible for randomization.

Interventionen

  • Medizinprodukt Edwards EVOQUE Tricuspid Valve Replacement (TTVR) System

    Transcatheter Tricuspid Valve Replacement

  • Medizinprodukt Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System

    Transcatheter Tricuspid Valve Replacement

Endpunkte

  1. Primärer Endpunkt

    Rate of Major Adverse Events (MAE)

    Zeitrahmen 30-days post-procedure

  2. Primärer Endpunkt

    Composite Endpoint: All-cause mortality, Heart failure hospitalization, and tricuspid valve reintervention

    Zeitrahmen 1-year post-procedure

  3. Sekundärer Endpunkt

    Tricuspid regurgitation (TR) grade reduction

    Total number of patients with at least one grade TR reduction

    Zeitrahmen 6 months post-procedure

  4. Sekundärer Endpunkt

    Change in quality of life (QoL) as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline

    KCCQ overall summary score is a patient-reported measure of health status. Scores range from 0 to 100 where higher scores reflect better quality of life

    Zeitrahmen 6 months post-procedure

  5. Sekundärer Endpunkt

    All-cause mortality

    Zeitrahmen 12 months post-procedure

  6. Sekundärer Endpunkt

    Heart failure hospitalization

    Zeitrahmen 12 months post-procedure

  7. Sekundärer Endpunkt

    New onset conduction disturbance (NOCD)

    Zeitrahmen 30 days post-procedure

  8. Sekundärer Endpunkt

    Total procedure time

    Zeitrahmen Procedure

  9. Sekundärer Endpunkt

    Right ventricle (RV) dysfunction

    Zeitrahmen 12 months post-procedure

Daten

Daten
Startdatum11. September 2026 (tatsächlich)
Primärer Abschluss1. September 2031 (geschätzt)
Abschluss1. April 2041 (geschätzt)
Erstveröffentlichung7. Januar 2026 (tatsächlich)
Zuletzt aktualisiert12. November 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtNovember 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

20 Studienzentren rekrutieren

United States

United States
EinrichtungStadtBundesland oder RegionStatus
Emory University Hospital MidtownAtlantaGeorgiaRekrutiert
University of Alabama at Birmingham (UAB) HospitalBirminghamAlabamaRekrutiert
Buffalo General Medical CenterBuffaloNew YorkRekrutiert
Northwestern Memorial HospitalChicagoIllinoisRekrutiert
The Christ HospitalCincinnatiOhioRekrutiert
Cleveland Clinic FoundationClevelandOhioRekrutiert
Hartford HospitalHartfordConnecticutRekrutiert
Cedars Sinai Medical CenterLos AngelesCaliforniaRekrutiert
Northwell Health North Shore University HospitalManhassetNew YorkRekrutiert
Abbott Northwestern HospitalMinneapolisMinnesotaRekrutiert
Morristown Medical CenterMorristownNew JerseyRekrutiert
Yale New Haven HospitalNew HavenConnecticutRekrutiert
Montefiore Medical CenterNew YorkNew YorkRekrutiert
NYU Langone Medical CenterNew YorkNew YorkRekrutiert
The Valley HospitalParamusNew JerseyRekrutiert
Abrazo Arizona Heart HospitalPhoenixArizonaRekrutiert
Kaiser Permanente San Francisco Medical CenterSan FranciscoCaliforniaRekrutiert
Los Robles Hospital & Medical CenterThousand OaksCaliforniaRekrutiert
Ascension Via Christi Saint FrancisWichitaKansasRekrutiert
Lankenau Institute for Medical ResearchWynnewoodPennsylvaniaRekrutiert

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

  1. 12. November 2026

    Studienzentrum hinzugefügt

    7 sites added (20 total)

    1320

  2. 25. September 2026

    Studienzentrum hinzugefügt

    9 sites added (13 total)

    413

  3. 28. Juli 2026

    Status geändert

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  4. 28. Juli 2026

    Rekrutierung eröffnet

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  5. 28. Juli 2026

    Studienzentrum hinzugefügt

    4 sites added (4 total)

    04